IL13 and atopic eczema: Lebrikizumab is a new monoclonal antibody that targets IL-13 which inhibits the formation of the signaling complex of the IL-13Rα1/IL-4Rα receptor in adult patients with moderate to severe atopic dermatitis [100,101,130,131].